Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAIM: Ipatasertib + Fulvestrant + Palbociclib in ER+/HER2- Breast Cancer
NCT04920708Phase 2Active, not recruiting
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Dec 2022
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ipatasertib in breast cancer, sponsored by Royal Marsden NHS Foundation Trust. Started Dec 2022; status: active, not recruiting.
02
Drugs
ipatasertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04920708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04920708.